Search

Switzerland: Pharma Appointment Dr. Klaus Moosmayer Selected as Novartis’ Chief Ethics Risk and Compliance Officer

| Editor: Ahlam Rais

With this appointment, Dr. Moosmayer will replace Shannon Thyme Klinger who was recently appointed Group General Counsel of the company. He is expected to commence operations from December 1, 2018.

Related Companies

Dr Klaus Moosmayer will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis.
Dr Klaus Moosmayer will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis.
(Source: Deposit Photos)

Basel/Switzerland – Novartis has recently announced the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.

Dr. Moosmayer has been the Chief Compliance Officer of Siemens since January 1, 2014. Prior to this, he served as the Chief Counsel Compliance at Siemens for four years. During this time he played a key role in building up Siemens' new, globally recognised compliance system.

Dr. Moosmayer is a recognised global leader in Ethics and Compliance. Since 2013, he has been Chair of the Anti-Corruption Taskforce of the Business and Industry Advisory Committee at the Organisation for Economic Co-operation and Development (OECD). Additionally, Dr. Moosmayer is the Vice Chair of Business Compliance for the current G20 presidency and also served as Chair of Business Compliance during the 2016/17 G20 presidency.

The role of Chief Ethics and Compliance Officer, reporting to the CEO, was created in 2014, this step elevated the Compliance function to the highest levels in the company. On April 1, 2018, the role was further expanded to include oversight of all risk management functions and became a member of the Executive Committee of Novartis.

(ID:45447123)